AC Immune SA

AC Immune operates with a market capitalization of CHF 307.36 million and a price-to-book ratio of 6.85, indicating a premium valuation relative to its book value. The company holds CHF 26.80 million in cash and equivalents, while its total liabilities amount to CHF 109.37 million, resulting in a debt-to-equity ratio of 0.1. The current ratio of 1.02 suggests that the company has a balanced short-term liquidity position, with current assets nearly matching current liabilities. Profitability metrics reveal a challenging financial landscape for AC Immune. The company reported a net loss of CHF 70.45 million and an operating loss of CHF 69.32 million in the latest period. Return on equity (ROE) is negative at -1.57, and return on assets (ROA) is also negative at -0.46, indicating that the company is not generating returns on its equity or asset base. These figures are below the industry median for profitability metrics, reflecting the high R&D costs typical in the biopharmaceutical sector. Geographically, AC Immune's revenue is concentrated in a limited number of markets, with a significant portion derived from clinical trials and partnerships in North America and Europe. The company's exposure to these regions increases its vulnerability to regulatory and market shifts in these key geographies. Looking ahead, AC Immune is projected to maintain a negative revenue trajectory, with no significant growth expected in the current fiscal year. The company's focus remains on advancing its pipeline of therapeutic candidates, particularly in Alzheimer's disease, which may take several years to reach commercialization. This long development cycle contributes to the company's current financial losses and limits near-term revenue visibility. Risk factors for AC Immune include the high costs and uncertainties associated with drug development, regulatory approval risks, and competition from larger pharmaceutical firms. The company's liquidity risk is currently low, supported by its cash reserves, but its dilution risk is also low, with no immediate filing-based flags detected. However, the company's reliance on equity financing for R&D could introduce dilution pressure in the future. Recent events include the continued advancement of its lead candidate, ACI-35, in clinical trials for Alzheimer's disease. The company has also engaged with multiple analysts, who have provided a mean price target of CHF 8.00, significantly higher than the current market price of CHF 3.02. This suggests that the market anticipates potential value creation from successful clinical outcomes.